Inclusion Criteria:  participants must provide at least 10 hours of care a week to a person with a diagnosis of dementia (including Alzheimer's disease (early onset or late onset), frontotemporal dementia, Lewy body dementia, Parkinsonian dementia, and mixed dementias) participants must be willing to provide informed consent participants have no planned travel during the study period participants must be able to comply with basic instructions participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale)  Exclusion criteria:  participants providing less than 10 hours a week of care to a person with dementia participants who are unable or unwilling to attend intervention sessions during the planned study period participants who are unable or unwilling to provide consent participants who are unable to sit comfortably for up to 75 minutes participants who are not exhibiting symptoms of stress, anxiety or insomnia participants with hearing impairment severe enough that they cannot perceive tones through ear buds participants anticipating ongoing use of alcohol or recreational drugs participants with known seizure disorder, or suicidal thoughts within the last 3 months participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list participants weighing more than 400 pounds (the weight limit of the chair used during intervention) participants currently enrolled in another intervention study prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month participants taking Medications that may affect the assessment of heart rate variability (beta blockers. Ongoing need for treatment with opiate, benzodiazepine, or anti-psychotic medications, anti-depressant medications (SSRI, or SNRI's), sleep medications such as zolpidem or eszopiclone, stimulants such as Adderall, Provigil, or Ritalin, or thyroid hormone)